Prothena Dirección
Dirección controles de criterios 3/4
El CEO de Prothena es Gene Kinney , nombrado en Sep 2016, tiene una permanencia de 9.67 años. compensación anual total es $5.90M, compuesta por 11.8% salario y 88.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $1.49M. La antigüedad media del equipo directivo y de la junta directiva es de 7.9 años y 11.3 años, respectivamente.
Información clave
Gene Kinney
Chief Executive Officer (CEO)
US$5.9m
Compensación total
| Porcentaje del salario del CEO | 11.75% |
| Permanencia del CEO | 9.7yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 7.9yrs |
| Promedio de permanencia en la Junta Directiva | 11.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 09
PRTA: Fast Track ATTR Program And Buybacks Will Support Future Upside
Analysts kept Prothena's fair value estimate steady at $21.00 with only small tweaks to the discount rate and long term assumptions, suggesting their price target is broadly unchanged while refining the supporting model inputs. What's in the News The U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for transthyretin amyloidosis with cardiomyopathy.Actualización de narrativa • Apr 22
PRTA: ATTR Milestones And Share Repurchase Plan Will Support Future Upside
Analysts maintained Prothena's fair value estimate at $21.00, citing largely unchanged assumptions regarding revenue growth, profit margin, discount rate, and a very large future P/E multiple. What's in the News Prothena has earned $150 million to date out of up to $1.2 billion in eligible milestone payments from Novo Nordisk under their ATTR amyloidosis agreement.Actualización de narrativa • Apr 02
PRTA: ATTR Milestones And Share Repurchase Will Drive Future Upside
Analysts have kept their price target for Prothena broadly unchanged at $21.00, with only slight adjustments to underlying assumptions on discount rate, revenue growth, profit margin and future P/E, in order to better reflect their current view of the stock's risk and earnings profile. What's in the News Prothena has earned $150 million to date of the total eligible milestone payments of up to $1.2 billion from Novo Nordisk under their ATTR amyloidosis agreement, including a recent $50 million milestone tied to a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA trial of coramitug for ATTR-CM (Key Developments).Actualización de narrativa • Mar 19
PRTA: Share Buyback And ATTR Milestones Will Support Future Upside
Analysts have nudged their price target on Prothena to $21.00 from $20.50, reflecting updated assumptions on growth, margins, and a very large prospective future P/E multiple. What's in the News Prothena has earned a total of $150 million to date from potential milestone payments of up to $1.2 billion under its ATTR amyloidosis agreement with Novo Nordisk, tied to clinical development and sales milestones (Key Developments).Actualización de narrativa • Mar 04
PRTA: Share Buyback And Index Inclusion Will Support Future Upside
Analysts now set their Prothena price target at about $20.50, compared with roughly $20.33 previously. This reflects updated assumptions around revenue growth, profit margins and future P/E levels.
Nueva narrativa • Feb 23
Bullish View Expects Partnered Neurology Pipeline And CYTOPE Platform To Reshape Long-Term Prospects
Catalysts About Prothena Prothena is a late stage biotech company focused on protein misfolding and neurodegenerative diseases through partnered and wholly owned antibody and CYTOPE programs. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Feb 18
PRTA: Index Inclusion And ALS Platform Milestones Will Drive Future Upside
Analysts maintained their Prothena fair value estimate at $20.33 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this unchanged price target. What's in the News Prothena Corporation plc was added to the S&P Biotechnology Select Industry Index, which can increase visibility for the stock among index-tracking funds and sector-focused investors (Key Developments).Actualización de narrativa • Feb 03
PRTA: Future Milestones From ALS Platform And ATTR Program Will Drive Upside
Analysts have trimmed their price target for Prothena to about US$20.33 per share, reflecting slightly adjusted assumptions around discount rate, profit margin, and future P/E that fine tune rather than overhaul their prior view. What's in the News Prothena was added to the S&P Biotechnology Select Industry Index, putting the stock into a tracked industry benchmark that some index funds and ETFs follow (Index Constituent Adds).Actualización de narrativa • Jan 20
PRTA: Partnered Royalties And Milestones Will Drive Upside Over Next 12 Months
Narrative update Analysts have lifted their price target on Prothena to US$36 from US$15, highlighting the value they see in the partnered pipeline and its potential for net sales royalties and milestone payments over the catalyst-heavy year ahead. Analyst Commentary Bullish analysts are pointing to the recent price target revision to US$36 as a signal that the market may be underappreciating the potential value of Prothena's partnered programs, especially the royalty and milestone streams that could build over time.Actualización de narrativa • Jan 05
PRTA: Partnered Royalties And Milestones Will Drive Upside Over Catalyst-Rich Year
Narrative Update Analysts have raised their price target on Prothena to US$36 from US$15, citing what they describe as strong potential in the company's partnered pipeline, including expected net sales royalties and milestone payments over the coming year and in subsequent periods. Analyst Commentary Recent commentary from bullish analysts centers on the uplift in the price target to US$36, tied directly to how they see Prothena executing on its partnered programs and the potential cash flows that could come from those collaborations.Actualización de narrativa • Dec 18
PRTA: Partnered Pipeline Milestones Will Drive Upside Over Catalyst-Rich Year Ahead
Analysts have significantly raised their price target on Prothena to $36 from $15, reflecting increased confidence in the lucrative potential of its partnered pipeline, including expected net sales royalties, milestone payments, and a catalyst-rich outlook over the next year. Analyst Commentary Bullish analysts highlight that the substantial price target increase is grounded in greater conviction around Prothena's partnered pipeline, which they see as a key driver of long term value creation and multiple expansion.Artículo de análisis • Dec 11
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Actualización de narrativa • Dec 04
PRTA: Partnered Pipeline Milestones Will Drive Upside Over Catalyst-Rich Year Ahead
Analysts have lifted their fair value estimate for Prothena by about $2 per share, citing stronger long term revenue growth expectations from its partnered pipeline, lucrative royalty and milestone economics, and a robust catalyst calendar that they believe offers substantial upside potential. Analyst Commentary Recent adjustments to Prothena's valuation reflect a growing conviction that the company’s partnered programs and associated economics could materially enhance long term growth, though execution and timing risks remain key variables for investors.Actualización de narrativa • Nov 20
PRTA: Upcoming Partnered Pipeline Milestones Will Drive Substantial Upside Over Next Year
Analysts have increased their price target for Prothena, raising it from $16.50 to $18.33. They cite optimism about the company's partnered pipeline and upcoming catalysts as key drivers for this upward revision.Actualización de narrativa • Nov 05
PRTA: Upcoming Pipeline Milestones Will Drive Bullish Momentum Over Next 12 Months
Analysts have increased their price target for Prothena significantly, raising it from $15 to $36. They cite the company's strong partnered pipeline as well as substantial potential from upcoming catalysts and milestone payments.Actualización de narrativa • Oct 22
Analysts Maintain Prothena Price Target as Valuation Adjustments Reflect Recent Clinical Results
Analysts have marginally raised their price target for Prothena from $13.00 to $13.00. They cited slight adjustments in discount rate and profit margin assumptions as drivers for the updated valuation.Actualización de narrativa • Oct 08
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Analysts have raised Prothena's fair value estimate by $1.00 to $13.00, citing improved profit margin forecasts and a slightly lower projected future price-to-earnings ratio. What's in the News Prothena announced results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease.Actualización de narrativa • Sep 13
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Prothena’s consensus price target has been revised down to $12.00, reflecting weaker expectations primarily due to a notable decline in net profit margin and a reduced future P/E multiple. What's in the News Prothena reported Phase 1 ASCENT program results for PRX012 in early symptomatic Alzheimer's, showing stable pharmacokinetics, low immunogenicity, significant amyloid reduction, but higher ARIA-E rates compared to FDA-approved antibodies; company plans to seek partnerships for PRX012 and PRX012-TfR.Actualización de narrativa • Aug 29
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Despite a sharp upward revision in both revenue growth and net profit margin forecasts for Prothena, the consensus analyst price target has significantly decreased from $24.29 to $15.00. What's in the News Phase 1 ASCENT results for PRX012 in early symptomatic Alzheimer's showed promising amyloid plaque reduction and pharmacokinetics, but higher ARIA-E rates than approved therapies; Prothena will seek partnership to advance PRX012 and its preclinical Ab-TfR antibody.Artículo de análisis • May 29
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on Prothena Corporation plc ( NASDAQ:PRTA ) - they aren't optimistic, having...Seeking Alpha • May 27
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place
Summary Prothena Corporation plc's phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis failed, leading to program termination and workforce reduction. Despite Phase 3 AL Amyloidosis trial failure, I maintain a Hold rating due to Prothena's robust pipeline, including Alzheimer's, Parkinson's, and ATTR-CM candidates. Key near-term catalysts include phase 1 PRX012 Alzheimer's data mid-2025 and other releases going forward, plus data updates for candidates prasinezumab and coramitug for PD and ATTR-CM. The Alzheimer's Disease market, in the 8 major markets [8MM] is expected to reach $19.3 billion by 2033; About between 5% to 6% of AD patients are early-symptomatic. Read the full article on Seeking AlphaArtículo de análisis • May 22
Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge
Unfortunately for some shareholders, the Prothena Corporation plc ( NASDAQ:PRTA ) share price has dived 27% in the last...Artículo de análisis • Apr 02
Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
Prothena Corporation plc ( NASDAQ:PRTA ) shares have had a horrible month, losing 26% after a relatively good period...
Nueva narrativa • Mar 26
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.Seeking Alpha • Mar 03
Prothena Corporation: Multiple Failures Make It Risky
Summary Prothena Corporation focuses on neurodegenerative diseases with a diverse pipeline, including Birtamimab for AL amyloidosis, which is in a phase 3 trial. Despite past trial failures, Birtamimab showed a survival benefit in severe AL amyloidosis patients, leading to a new phase 3 study. Financially, Prothena has a market cap of $850mn and a cash runway of 5-10 quarters, but is heavily spending on R&D. I recommend avoiding PRTA due to unpredictable upcoming data and past trial failures, making it risky and potentially un-investible. Read the full article on Seeking AlphaArtículo de análisis • Feb 22
Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think
It's been a good week for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, because the company has just released...Artículo de análisis • Jan 24
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 6.2x Prothena Corporation plc ( NASDAQ:PRTA ) may be sending bullish signals...Seeking Alpha • Dec 22
Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Summary Prothena's stock surged 34% despite Prasinezumab missing its Phase IIb primary endpoint, as Roche continues to invest. Prothena's pipeline includes multiple clinically staged drugs, with partnerships with major pharma companies, offering high-risk/high-reward potential. Investors should be cautious due to Prothena's 61% stock decline in 2024, but meaningful clinical success could create a buying opportunity. Prothena is rated as a HOLD, with upcoming catalysts in Parkinson's and Alzheimer's diseases that could fuel significant price appreciation. Read the full article on Seeking AlphaArtículo de análisis • Nov 06
Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Oct 18
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Summary Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful Phase 1 data for PRX012. PRX012, targeting amyloid beta for Alzheimer's, is Prothena's key value driver but remains in Phase 1, lagging competitors with similar drugs. Birtamimab's Phase 3 data has also faced delays, and while promising, it competes in a crowded market with limited patient populations. Despite a strong cash position, Prothena's pipeline progress and competitive landscape justify a downgrade to “Hold” until more substantial data is available. Read the full article on Seeking AlphaArtículo de análisis • Oct 02
Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Prothena Corporation plc ( NASDAQ:PRTA ) shareholders won't be pleased to see that the share price has had a very rough...Artículo de análisis • Jul 26
Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
You may think that with a price-to-sales (or "P/S") ratio of 14.9x Prothena Corporation plc ( NASDAQ:PRTA ) is a stock...Artículo de análisis • Jun 19
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Jun 07
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Summary Prothena Corporation is a late-stage biotech which specializes in proteinopathies and neurodegenerative diseases. They have a diverse pipeline. However, their main assets in attention currently are a first-in-class amyloid depleter, Birtamimab (wholly owned), and a Parkinson’s a-synuclein mAb, Prasinezumab (collab with Roche). Their revenue is primarily dependent on key milestone payments from collaborators. The stock has been dropping since its peak about a year ago, and I believe it still has room to drop for the foreseeable future due to the risk of failure of late-stage trials. Read the full article on Seeking AlphaArtículo de análisis • May 14
New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
Prothena Corporation plc ( NASDAQ:PRTA ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Feb 23
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients with Alzheimer's Disease in the ongoing phase 3 ASCENT-2 study. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031. BMS-986446 is being advanced in collaboration with Bristol-Myers Squibb with the big pharma having taken over the program going forward; Prothena received a $55 million milestone payment based off of it. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$151m |
| Dec 31 2025 | US$6m | US$693k | -US$244m |
| Sep 30 2025 | n/a | n/a | -US$280m |
| Jun 30 2025 | n/a | n/a | -US$303m |
| Mar 31 2025 | n/a | n/a | -US$110m |
| Dec 31 2024 | US$7m | US$654k | -US$122m |
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$172m |
| Dec 31 2023 | US$7m | US$631k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$141m |
| Mar 31 2023 | n/a | n/a | -US$128m |
| Dec 31 2022 | US$7m | US$601k | -US$117m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$1m |
| Mar 31 2022 | n/a | n/a | US$67m |
| Dec 31 2021 | US$5m | US$573k | US$67m |
| Sep 30 2021 | n/a | n/a | US$69m |
| Jun 30 2021 | n/a | n/a | -US$70m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$3m | US$554k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$91m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$3m | US$538k | -US$78m |
Compensación vs. Mercado: La compensación total de Gene($USD5.90M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.65M).
Compensación vs. Ingresos: La compensación de Gene ha sido consistente con los resultados de la empresa en el último año.
CEO
Gene Kinney (56 yo)
9.7yrs
Permanencia
US$5,896,045
Compensación
Dr. Gene G. Kinney, Ph D., is Chairman of the Board of Libra Therapeutics, Inc. Dr. Kinney has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and Octobe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.7yrs | US$5.90m | 0.29% $ 1.5m | |
| Chief Financial Officer | 13.2yrs | US$2.66m | 0.19% $ 948.7k | |
| Chief Operating Officer | 4.6yrs | US$2.81m | 0.25% $ 1.3m | |
| Chief Scientific Officer | 8.9yrs | US$2.41m | 0.16% $ 829.6k | |
| Chief Development Officer | 1.7yrs | US$2.42m | 0.16% $ 829.6k | |
| Chief Accounting Officer & Controller | 13yrs | sin datos | 0.048% $ 244.0k | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Chief Legal Officer & Company Secretary | 6.8yrs | US$1.18m | 0.15% $ 780.8k | |
| Sr. Director & Head of Exploratory Research | no data | sin datos | sin datos | |
| Chief Strategy Officer | less than a year | sin datos | 0.13% $ 653.4k |
7.9yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PRTA es experimentado (7.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.7yrs | US$5.90m | 0.29% $ 1.5m | |
| Independent Director | 3.8yrs | US$160.83k | 0% $ 0 | |
| Independent Director | 13.4yrs | US$175.83k | 0.0023% $ 11.9k | |
| Independent Chairman | 2.3yrs | US$192.92k | 0% $ 0 | |
| Independent Chair Emeritus | 21yrs | US$175.83k | 0.00046% $ 2.4k | |
| Independent Director | 13.4yrs | US$183.33k | 0% $ 0 | |
| Independent Director | 12.8yrs | US$172.33k | 0.0080% $ 41.1k | |
| Independent Director | 3yrs | US$170.56k | 0% $ 0 |
11.3yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de PRTA son experimentados ( 11.3 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/18 08:09 |
| Precio de las acciones al final del día | 2026/05/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Prothena Corporation plc está cubierta por 24 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |